News
October 24, 2008
The Lilly TB Drug Discovery Initiative announced its first acquisition of compounds for further development into tuberculosis (TB) drug candidates. Agreements were reached with Summit plc (LSE: SUMM) of Oxfordshire, UK, and the Microbial Chemistry Research Foundation (MCRF) of Tokyo for two compounds that have shown potential in initial testing.
October 24, 2008
Pharmaceutical companies Eli Lilly and Merck have released their "molecular libraries" -- which include data on the chemistry and structure of drug components -- to allow scientists from the Infectious Disease Research Institute to research new tuberculosis treatments, the Seattle Times reports.
October 24, 2008
New experimental vaccines designed to protect against a certain strain of tuberculosis could allow other strains of the disease to survive and lead to drug resistance.
October 24, 2008
The Global Alliance for TB Drug Development (TB Alliance) announced a new grant and pledge of up to $40 million over the next five years from the United States Agency for International Development (USAID).
October 24, 2008
Three naturally occurring antibacterial compounds could help researchers develop new treatments for tuberculosis and prevent drug-resistant TB.
October 24, 2008
The Global Alliance for TB Drug Development (TB Alliance) and sanofi-aventis announced that they have entered into a collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis.
October 3, 2008
TB study of the pulmonary device called the Lung Flute®, a small, flute-shaped plastic device that can assist in harvesting sputum for diagnostic purposes, will be presented at the European Respiratory Society’s Annual Congress on October 6, 2008.
October 3, 2008
The antituberculosis activity of the front-line drug pyrazinamide (PZA), a weak acid (pyrazinoic acid) precursor, can be enhanced by inhibitors of energy metabolism and anaerobiosis.
October 3, 2008
This literature review considers new potential first-line antituberculosis drug candidates, in particular those with novel mechanisms of action, as these are most likely to prove effective against resistant strains.
October 3, 2008
PolyMedix, Inc. presented pre-clinical in vitro data describing the activity of a variety of their novel small molecule defensin mimetic antibiotic compounds against Mycobacterium tuberculosis.
October 3, 2008
A series of nine polypyridyl-ruthenium (II) complexes (N-ligands = 2,2'-bipyridines; 2,2'-6',2'-terpyridines, di-alkyloxy-2,2'-6,2-bipyridine-3,3'-di-carboxylates), were tested against Mycobacterium tuberculosis and reveal remarkable activity.
October 3, 2008
Researchers present in this study a new workflow for the identification and prioritization of potential compounds targeted against Mycobacterium tuberculosis dihydrofolate reductase, an important folate cycle enzyme and a validated target for the development of anti-tubercular agents.
September 25, 2008
The computer modelling for novel anti-TB drugs yield a promising lead compound.
September 25, 2008
Consortiums and high-level partnerships are needed to research new treatments and diagnostic tools aimed at controlling tuberculosis.
September 25, 2008
First-phase clinical trials of a live TB vaccine are being conducted in Neuss, Germany.
September 25, 2008
The recently identified diarylquinoline R207910 (also called TMC207) as an inhibitor of ATP synthase with a remarkable activity against replicating mycobacteria.
September 25, 2008
SRI International, an independent nonprofit research and development organization, announced the initiation of a tuberculosis (TB) preclinical drug evaluation program in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH).
September 12, 2008
The second phase of the Integrated Health Care program to control tuberculosis has been implemented in Zimbabwe's capital of Harare.
September 12, 2008
For the first time in 80 years, a very promising live tuberculosis vaccine has reached the clinical trial stage in Germany.
September 12, 2008
Bacteria save energy by producing proteins that moonlight, having different roles at different times, may protect the microbes from being killed. The moonlighting activity of one enzyme from the tuberculosis bacterium makes it partially resistant to a family of broad-spectrum antibiotics.
Displaying 1 through 20 of 710 items.
